Hsbc Holdings PLC Buys 304,334 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Hsbc Holdings PLC increased its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 46.3% in the first quarter, Holdings Channel.com reports. The firm owned 961,140 shares of the company’s stock after buying an additional 304,334 shares during the quarter. Hsbc Holdings PLC’s holdings in Teva Pharmaceutical Industries were worth $28,789,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd acquired a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $25,000. Allworth Financial LP grew its stake in shares of Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after buying an additional 329 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Teva Pharmaceutical Industries by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after buying an additional 345 shares in the last quarter. Global Retirement Partners LLC increased its holdings in shares of Teva Pharmaceutical Industries by 27.3% during the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after buying an additional 292 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its stake in shares of Teva Pharmaceutical Industries by 567.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,334 shares of the company’s stock valued at $42,000 after acquiring an additional 1,134 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 10,679 shares of the company’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total transaction of $384,444.00. Following the sale, the chief accounting officer owned 20,016 shares of the company’s stock, valued at approximately $720,576. This represents a 34.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Eliyahu Sharon Kalif sold 106,563 shares of the stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $34.10, for a total value of $3,633,798.30. Following the sale, the executive vice president owned 65,621 shares of the company’s stock, valued at approximately $2,237,676.10. The trade was a 61.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 465,931 shares of company stock valued at $16,332,989 over the last 90 days. 0.54% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $31.36 on Wednesday. The company has a market capitalization of $36.05 billion, a PE ratio of 23.58, a P/E/G ratio of 3.27 and a beta of 0.86. The company has a 50 day simple moving average of $33.57 and a two-hundred day simple moving average of $32.70. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $14.99 and a fifty-two week high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. The firm had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. Research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.99 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on TEVA shares. Bank of America raised their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 9th. Piper Sandler reaffirmed an “overweight” rating and issued a $42.00 target price (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, April 30th. Truist Financial increased their target price on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Barclays lifted their price target on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Finally, JPMorgan Chase & Co. boosted their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and a consensus price target of $41.78.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.